Join Growin Stock Community!

Steris plcSTE.US Overview

US StockHealthcare
(No presentation for STE)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

STE AI Insights

STE Overall Performance

STE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

STE Recent Performance

-2.16%

Steris plc

0.05%

Avg of Sector

-0.31%

S&P500

STE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

STE Key Information

STE Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

STE Profile

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

Price of STE

STE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

STE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
7.21
PE Ratio (TTM)
35.20
Forward PE
23.11
PS Ratio (TTM)
4.25
PB Ratio
3.49
Price-to-FCF
25.96
METRIC
VALUE
vs. INDUSTRY
Gross Margin
44.11%
Net Margin
12.15%
Revenue Growth (YoY)
14.39%
Profit Growth (YoY)
16.31%
3-Year Revenue Growth
7.16%
3-Year Profit Growth
7.92%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
7.21
PE Ratio (TTM)
35.20
Forward PE
23.11
PS Ratio (TTM)
4.25
PB Ratio
3.49
Price-to-FCF
25.96
Gross Margin
44.11%
Net Margin
12.15%
Revenue Growth (YoY)
14.39%
Profit Growth (YoY)
16.31%
3-Year Revenue Growth
7.16%
3-Year Profit Growth
7.92%

  • When is STE's latest earnings report released?

    The most recent financial report for Steris plc (STE) covers the period of 2026Q3 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating STE's short-term business performance and financial health. For the latest updates on STE's earnings releases, visit this page regularly.

  • Where does STE fall in the P/E River chart?

    According to historical valuation range analysis, Steris plc (STE)'s current price-to-earnings (P/E) ratio is 34.94, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of STE?

    According to the latest financial report, Steris plc (STE) reported an Operating Profit of 270M with an Operating Margin of 18.05% this period, representing a growth of 10.07% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is STE's revenue growth?

    In the latest financial report, Steris plc (STE) announced revenue of 1.5B, with a Year-Over-Year growth rate of 9.17%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does STE have?

    As of the end of the reporting period, Steris plc (STE) had total debt of 2.05B, with a debt ratio of 0.19. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does STE have?

    At the end of the period, Steris plc (STE) held Total Cash and Cash Equivalents of 423.7M, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does STE go with three margins increasing?

    In the latest report, Steris plc (STE) achieved the “three margins increasing” benchmark, with a gross margin of 43.8%%, operating margin of 18.05%%, and net margin of 12.9%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess STE's profit trajectory and future growth potential.

  • Is STE's EPS continuing to grow?

    According to the past four quarterly reports, Steris plc (STE)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.96. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of STE?

    Steris plc (STE)'s Free Cash Flow (FCF) for the period is 209.9M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 13.84% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of STE?

    The latest valuation data shows Steris plc (STE) has a Price-To-Earnings (PE) ratio of 34.94 and a Price/Earnings-To-Growth (PEG) ratio of 63.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.